Informationen:
Fehler:
ID
43983
Beschreibung
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00663429
Link
https://clinicaltrials.gov/show/NCT00663429
Stichworte
Versionen (2)
- 04.07.17 04.07.17 -
- 20.09.21 20.09.21 -
Hochgeladen am
20. September 2021
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Neuroendocrine Carcinoma NCT00663429
Eligibility Neuroendocrine Carcinoma NCT00663429
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Neuroendocrine Carcinoma NCT00663429
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
ID.1
Item
1. subject was enrolled in protocol no. cp-106 and successfully completed 12 treatment cycles.
boolean
C0087111 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,2])
ID.2
Item
2. subject must have been classified as a responder at the time of completion of protocol no. cp-106 [i.e., sd or better per recist committee criteria or stable symptoms or better (defined as an average daily frequency of bowel movements, flushing episodes and/or wheezing episodes that is the same as or less than the average daily frequency of bowel movements, flushing episodes and/or wheezing episodes recorded during the 14-day screening period prior to enrollment in protocol no. cp-106)].
boolean
C0012240 (UMLS CUI [1,1])
C0919876 (UMLS CUI [1,2])
C0919876 (UMLS CUI [1,2])
ID.3
Item
3. subject must understand and voluntarily sign the informed consent document.
boolean
C0021430 (UMLS CUI [1])
ID.4
Item
4. subject must have adequate organ function defined as follows: absolute granulocyte count (agc) >1,500/mm3, hemoglobin >8 g/dl, platelets >100,000/mm3, serum bilirubin <1.5 x upper limit of normal (uln), serum creatinine <1.5 mg/dl, sgot ≤grade 1 per nci ctcae, sgpt ≤grade 1 per nci ctcae.
boolean
C0678852 (UMLS CUI [1])
ID.5
Item
5. women of child bearing potential (wcbp) must have a negative serum or urine pregnancy test. in addition sexually active wcbp must agree to use adequate contraceptive methods (oral, injectable or implantable hormonal contraceptive; tubal ligation; intra-uterine devices; barrier contraceptive with spermicide; or vasectomized partner).
boolean
C0032961 (UMLS CUI [1,1])
C0009862 (UMLS CUI [1,2])
C0009862 (UMLS CUI [1,2])
ID.6
Item
1. subject who was enrolled in protocol no. cp-106 and who did not successfully complete 12 treatment cycles.
boolean
C0087111 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,2])
ID.7
Item
2. if wcbp, pregnant, lactating or not using adequate contraception.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0009862 (UMLS CUI [1,3])
C0006147 (UMLS CUI [1,2])
C0009862 (UMLS CUI [1,3])
ID.8
Item
3. clinically relevant active infection or serious co-morbid medical conditions that are uncontrolled or whose control may be jeopardized by atiprimod treatment.
boolean
C3714514 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,2])
ID.9
Item
4. psychiatric disorders rendering subjects incapable of complying with the requirements of the protocol.
boolean
C0004936 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,2])
ID.10
Item
5. any condition which, in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C0012634 (UMLS CUI [1])
ID.11
Item
6. as atiprimod is a potent inhibitor of cyp2d6, the use of drugs that are substrates of cyp2d6 (e.g. beta blockers, antidepressants, and antipsychotic;) will not be allowed while on study.
boolean
C0057223 (UMLS CUI [1,1])
C1579206 (UMLS CUI [1,2])
C1579206 (UMLS CUI [1,2])